Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of INCB018424 in Patients with Advanced Hematologic Malignancies.

Trial Profile

Phase II Study of INCB018424 in Patients with Advanced Hematologic Malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 18 Aug 2015 Planned primary completion date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top